Clinical Trial

Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated June 13, 2023 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The study main objective is to assess the immune status of children and adults who have never vaccinated, they will receive the first dose of 17DD yellow fever vaccine provided by the study and will be monitored for 10 years. Depending on the results of the analyzed of the data, the period of monitoring may be extended.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2015-09-17; most recent amendment 2023-06-12.
Status change: Recruiting → Active, Not Recruiting 2018-07-17
Status change: Not Yet Recruiting → Recruiting 2016-07-07
Trial Details
NCT Number NCT02555072
Lead Sponsor The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Collaborators: Ministry of Health, Brazil
Conditions Yellow Fever Vaccine, Immunity
Enrollment 4,761 participants
Start Date 2016-07
Primary Completion 2026-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2023-06-13